EHS
EHS

Therachon Raises $60 Million Mezzanine Financing to Advance Lead Program in Achondroplasia and to Expand Rare Disease Pipeline


BASEL, Switzerland–(BUSINESS WIRE)–Therachon AG, a clinical-stage biotechnology company focused on rare diseases, today announced it has completed a $60 million mezzanine financing led by Novo Holdings and joined by new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital Management LLC. Existing investors Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative also participated. Therachon plans to use the proceeds to advance the company’s le

Source link

EHS
Back to top button